At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
PRM-151 +1 morebiological
Likely dose
PRM-151 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
In Brief
A Phase 2 clinical trial evaluating PRM-151 and placebo for Idiopathic Pulmonary Fibrosis. Completed, enrolled 117 participants across 18 sites in 7 countries.
Detailed Summary
This study is a Phase 2, randomized, double-blind, placebo controlled, pilot study designed to evaluate the efficacy and safety of PRM-151 administered through Week 24 to subjects with IPF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesCzechia, Germany, Italy, Netherlands, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedSep 16, 2015
Enrollment StartSep 1, 2015
Primary CompletionMay 2, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.8 years ago
Interventions
PRM-151biological
PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
placeboother
Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks